People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Other Health Care, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Wugen, Inc. | — | Other Health Care | Series D+ | $245.2M | $870.3M | 2025 |
| Avalyn Pharma Inc. | — | Biotechnology | Series D+ | $244.0M | $2.7B | 2023 |
| Spruce Biosciences, Inc. | — | Biotechnology | Series C | $191.6M | $274.3M | 2020 |
| Reneo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $159.4M | $519.3M | 2017 |
| Sparrow Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $73.3M | $386.2M | 2024 |
| Lyric Pharmaceuticals Inc. | — | Pharmaceuticals | Series B | $26.8M | $910.8M | 2015 |
| Curzion Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $3.5M | $133.1M | 2019 |
Niall O'Donnell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Niall O'Donnell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bali Muralidhar | 3 | 3 |
| Ed Mathers | 2 | 11 |
| Michael Grey | 2 | 10 |
| Tiba Aynechi | 2 | 9 |
| Peter Thompson | 1 | 16 |
| Jonathan Root | 1 | 16 |
| Jonathan Leff | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Kevin Lalande | 1 | 8 |
| Drew Dennison | 1 | 7 |
| Casey Cunningham | 1 | 7 |
| Klaus Veitinger | 1 | 6 |
| David Katz | 1 | 6 |
| Zach Scheiner | 1 | 6 |
| Peter Moldt | 1 | 6 |
| Bosun Hau | 1 | 6 |
| Matthew Cooper | 1 | 5 |
| Peter Kiener | 1 | 4 |
| Kenneth Harrison | 1 | 4 |
| Jason Hong | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.